Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 32, Issue 4, 2013, Pages 383-388

  Bryant, Kristina A ^a   Gurtman, Alejandra ^b   Girgenti, Douglas ^b   Reisinger, Keith ^c   Johnson, Anthony ^d   Pride, Michael W ^b   Patterson, Scott ^b   Devlin, Carmel ^b   Gruber, William C ^b   Emini, Emilio A ^b   Scott, Daniel A ^b  

^a University of Louisville School of Medicine   (United States)

^b PFIZER INC   (United States)

^c Primary Physicians Research   (United States)

^d Arkansas Pediatrics   (United States)

Author keywords

13 valent pneumococcal vaccine; Concomitant administration; Immune response; Infants; Toddlers

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CHICKENPOX; DIPHTHERIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HAEMOPHILUS INFECTION; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES; MUMPS; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; RUBELLA; TETANUS;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; TETANUS TOXOID; UNITED STATES;

EID: 84876298593     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318279e9a9     Document Type: Article

References (13)

1. Whitney CG, Farley MM, Hadler J, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polys accharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
2. Poehling KA, Lafleur BJ, Szilagyi PG, et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics. 2004;114:755-761.
3. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
4. Beall B, McEllistrem MC, Gertz RE Jr, et al.; Active Bacterial Core Surveillance Team. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol. 2006;44:999-1017.
5. Byington CL, Korgenski K, Daly J, et al. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J. 2006;25:250-254.
6. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26:46 8-472.
7. Centers for Disease Control and Prevention. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae - Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep. 2007;56:1077-1080.
8. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years - United States, 2010. MMWR Morb Mortal Wkly Rep. 2010;58:1-4.
9. Yeh SH, Gurtman A, Hurley DC, et al.; 004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126:e493-e505.
10. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17:1017-1026.
11. Gimenez-Sanchez F, Kieninger DM, Kueper K, et al.; 501 and 006 study groups. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29:6042-6048.
12. Tichmann-Schumann I, Soemantri P, Behre U, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2005;24:70-77.
13. Knuf M, Habermehl P, Cimino C, et al. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine. 2006;24:4727-4736.